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Abstract. Lymph node metastases are responsible for shorter 
survival in oral squamous cell carcinoma (OSCC). The aim of 
the present study was to assess the node metastasis frequency 
and survival according to the node metastasis features in 121 
neck dissections (NDs) performed for OSCC, identifying 
evidence-based correlations and contrasts with previous 
literature. The retrospective study involved 121 patients 
affected by OSCC who had undergone modified radical ND 
(MRND) for therapeutic, elective reasons or after intraopera-
tive positivity to metastasis of sentinel lymph nodes (SLN+). 
Node metastasis frequency and behaviour (typical vs. atypical) 
and their number and distribution according to pre-surgical 
cTNM cancer staging were considered and overall survival 
Kaplan-Meier curves were calculated for each group in order 
to compare mortality according to ND type (elective, thera-
peutic, after SLN+), lymph node metastatic pattern (typical 
or atypical), size (micrometastasis vs. macrometastasis) and 
number. Results showed statistically significant different 
overall survival according to pre-surgical staging, number of 
lymph nodes harvested and intent to surgery. Sentinel lymph 
node resulted in the sole positive node affected by metastasis 
in small cT1- cT2/cN0 OSCC and an ND subsequent to its 
positivity during intraoperative assessment may be considered 
an overtreatment.
Introduction
Oral squamous cell carcinoma (OSCC) is the sixth most 
common cancer internationally, accounting for ~5% of 
all malignant tumours worldwide (1). OSCCs commonly 
metastasize to cervical lymph nodes. Each tumour generally 
metastasizes in a particular group of cervical lymph nodes and 
the principles and criteria governing neck dissection (ND) are 
based on the primary tumour characteristics, according to the 
cTNM staging and its primary site (2,3).
Cervical lymph node metastases (LNMs) are key malig-
nancy criteria in OSCC (4). Their presence influences the 
therapeutic plan and prognosis, since it is associated with a 
50% decrease in survival (5,6).
The selection of OSCC cases requiring ND depends mainly 
on the clinical TNM staging (cTNM). cTNM provides a stage 
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grouping based on the extent of the primary tumour (T score), 
the involvement of the regional, cervical, lymph nodes (N 
score) and the detection of distant metastases (M score) (2,3,7). 
These parameters are accurately quantified after performing a 
series of clinical-instrumental examinations such as PET, total 
body CT scan, neck echo-color Doppler, fibrolaryngoscopy, 
esophageal-gastric-duodenoscopy, bronchoscopy and, if any 
doubts persist, fine needle aspiration biopsy (FNAB) and 
biopsy must be also performed.
Once clinical T, N and M parameters have been defined, an 
ND is mandatory for the OSCCs showing cervical LNMs (any 
cT/N+) and for locally advanced primary tumours (cT3 or cT4) 
with clinically undetectable LNMs (cN0).
Based on the intent or purpose, NDs have been also clas-
sified into therapeutic and elective. Therapeutic NDs are 
performed in OSCCs with cervical metastases detected in 
clinical preoperative setting (any T/N+). Elective NDs are 
selected for locally advanced primary tumours (T3 or T4) 
with clinically undetectable LNMs (cN0) (8). NDs are also 
performed in the cases of small primary tumours clinically 
negative to node involvement (cT1-T2/N0) that during intra-
operative assessment of their sentinel lymph node reveal 
positivity to metastasis (9).
Both ND anatomical extent and involvement of surrounding 
structures are related to the node levels involved in the dissec-
tion and they are planned on the basis of the OSCC primary 
site; correlations between primary site of the cancer and level 
of metastasis have been demonstrated and, to date, they aid the 
surgeon in the surgical ND management (10).
Currently, NDs are classified into four basic procedures 
according to the extent of different cervical lymph node groups 
and surrounding structures: radical ND, modified radical ND, 
(MRND) extended ND and selective ND (8,11).
Following histopathological assessment of the tumour 
margins of excision and after the evaluation of the involve-
ment of the surrounding structures, adjuvant therapy may also 
be performed: radiotherapy for T4 tumours with free surgical 
margins and/or ≥N2; and both radiotherapy and chemo-
therapy for tumours with any N+ plus extracapsular spread 
(ECS) and ones with any T and positive or close margins or 
perineural invasion and/or neoplastic vascular embolization. 
T1-3 tumours with free margins and pN0/pN1 do not require 
adjuvant treatment (12,13).
Despite the progress in pre-surgical instrumental exami-
nations (head and neck CT scan, neck echo-color Doppler, 
fibrolaryngoscopy, esophageal-gastric-duodenoscopy, 
broncho scopy and PET), clinical lymph node staging is not 
completely error-free due to false positivity in the presence of 
reactive lymph nodes, non metastatic lymph node enlargement 
and false negativity for small- or micrometastases clinically 
undetectable (14,15). Finally, the controversial role of sentinel 
lymph node positivity and the surgical morbidity after ND 
have led to the evaluation of alternative and super-selective 
surgeries in order to reduce the overtreatments (15,16-18).
For these reasons, further in-depth studies regarding the 
behaviour of lymph node cervical metastases may be useful 
to refine therapeutic management, thereby decreasing the 
overtreatment-related morbidity and mortality.
The aim of the present study was to define LNM frequency, 
topographic distribution, size (micrometastases vs. macrome-
tastases) and histological pattern correlating them with the 
clinical features of primary tumour in 121 OSCC patients who 
had undergone ND, considering the survivals related to their 
presence/absence and the morbidity related to the negative ND 
and due to the neck surgery, comparing our results with the 
literature and suggesting an evidence-based re-evaluation of 
the therapeutic approach to ND.
Materials and methods
Study population and clinical pathological data. Resection 
specimens from 121 patients who had undergone ND 
surgery for OSCC at the National Cancer Institute of Naples, 
‘G. Pascale’, Italy, between the years 1993-2004, formed 
the basis of the present retrospective analysis. All patients 
underwent MRND for OSCC (11,19). Patients who had had 
previous surgery (other than diagnostic biopsy) were excluded. 
Throughout the time period of the study, the resection speci-
mens were performed by the same surgical team and were 
assessed by the same pathological team. Pathological report 
and topography of the extent and location of the metastatic 
disease for each patient were reviewed and number, size 
and histological patterns of LNM-positive cases (pN+) were 
re-evaluated according to previous literature (14,15,20,21) in 
order to calculate frequency, distribution and other significant 
statistical correlations existing between primary tumour 
features and pN+.
The series comprised 80 males (mean age of 63.10±10.79 
years; range, 30-83 years, median 63 years) and 41 females 
(mean age, 63.12 ±15.19 years; range, 25-86 years, median, 
65 years). The cTNM staging was assessed according to the 
6th edition AJCC (2) since data refer to the period between 
1999-2004. Patient demographic and clinical characteristics of 
the 121 cases are summarized in Table I.
Pre-operative, operative and post-operative protocols. At the 
National Cancer Institute of Naples ‘G. Pascale’, Italy, the selec-
tion of OSCC cases requiring ND depends on the cTNM (2). 
cTNM parameters are accurately quantified after performing a 
series of clinical-instrumental examinations such as PET, total 
body CT scan, neck echo-color Doppler, fibrolaryngoscopy, 
esophageal-gastric-duodenoscopy, bronchoscopy and, if any 
doubts persist, fine needle aspiration biopsy (FNAB) and 
biopsy.
According to the literature, MRNDs are considered 
mandatory for the OSCCs clinically showing cervical LNMs 
(any cT/N+ and therapeutic ND), for locally advanced primary 
tumours with clinically undetectable LNMS (cT3/N0 and cT4/
cN0, elective ND) and in the cases of small primary tumours 
clinically negative to node involvement (cT1-T2/N0) that 
during intraoperative assessment of their sentinel lymph node 
reveal a positivity to metastasis (SLN+) (8,9).
For the ND surgical approach, we adopted MRND (10), thus 
involving levels I-IV for all oral sub-sites, except for trigone, 
posterior tongue and anterior pillar where ND extended until 
level V; level IIB was always comprised.
After surgery and histopathological assessment of the 
margins of excision of the primary tumour and after the 
evaluation of the involvement of the surroundings structures, 
adjuvant therapy was performed; radiotherapy for T4 tumours 
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with free-surgical margins and/or ≥N2, and both radiotherapy 
and chemotherapy both for tumours with any N+ plus ECS, 
tumours with any T and positive or close margins or perineural 
invasion and/or neoplastic vascular embolization tumours T1-3 
with free margins and pN0/pN1 were not enrolled for adjuvant 
treatments (12,13).
Since data refer to patients recruited from 1999 to 2004, 
prior to the last Cancer Staging Atlas publication, we consid-
ered the previous edition (2); hence, T4 tumours were not 
distinguished in T4a and T4b, consequently, stage IV has not 
been not subclassified into stages IVa, IVb and IVc (7).
Histopathological node metastasis classification. All 121 
lymph node specimens dissected were histopathologically 
re-evaluated for the present study. In order to detect microme-
tastases and to confirm the involvement of lymph nodes, the 
standardized sectioning protocol was performed. One H&E 
stained section was prepared from each block and examined 
for the presence of nodal involvement by tumour. If present, 
metastatic disease was reported. If node was negative or 
equivocal for metastatic disease, or positive for micrometas-
tases, the removed lymph nodes were also serially sectioned 
at 25-µm intervals 4 µm thick and alternately stained with 
H&E and immunohistochemical staining (IHC) using anti-
cytokeratin and EMA antibodies (Fig. 1) as described below. 
This pattern was continued throughout the entire block. Each 
immunostained component was always compared with adja-
cent sections stained by H&E.
Woolgar's classification criteria were considered in order 
to classify the type of metastasis (21,22). Woolgar distin-
guished metastatic lymph nodes into two groups with different 
prognosis and features: typical metastatic pattern as ‘orderly 
involvement of successive anatomical nodal levels, creating an 
inverted cone with maximum volume and maximum ECS at 
levels I or II and a gradual reduction in the volume/extent of 
metastasis at the numerically higher levels’ (21), vs. atypical 
metastatic pattern, termed ‘aberrant’ by Woolgar, and 
characterized by various features. The ones referring to the 
atypical pattern and considered in the present study were the 
involvement of ‘other’ anatomical groups of nodes (including 
parapharyngeal, facial, buccal, lingual and sublingual nodes), 
involvement of controlateral cervical lymph nodes, skipping of 
anatomical levels other than level I and the presence of a single 
micrometastasis (21).
Once defined, the histopathological features of node metas-
tases were correlated with the clinical and histopathological 
features of the primary tumour in order to establish statistical 
and prognostic correlations.
Immunohistochemistry. Histological and immunohis-
tochemical analyses were performed on formalin-fixed, 
paraffin-embedded tissue samples. Immunostaining was 
performed using the linked streptavidin-biotin horseradish 
peroxidase technique (LSAB-HRP). Antigen retrieval was 
performed by microwave heating, a first time for 3 min at 
650 W, a second and a third time for 3 min at 350 W, the slides 
immersed in 10 mM citrate buffer pH 6.0. After heating, the 
sections were blocked for 60 min with 1.5% horse serum 
(Santa Cruz Biotechnology) diluted in PBS buffer before 
reaction with the primary antibody (Ab). The primary mono-
clonal antibodies anti CK AE1/AE3 (dilution 1:50, pH 6.0; 
Dako, Carpinteria, CA, USA) and EMA (dilution 1:75, with 
protein K; Dako) were incubated overnight. After two washes 
Figure 1. Immunohistochemical H&E staining of a node metastasis showing 
cytokeratin and EMA positivity confirming the presence of OSCC metas-
tases in the lymph nodes evaluated.
Table I. Patient demographics and clinical characteristics.
 N (%)
Gender (male/female) 80/41 (66/34)
Male mean age, years (range) 63.10 (30-83)
Female mean age, years (range) 63.12 (25-86)
Primary T site
  Tongue 53 (44)
  Floor of the mouth 23 (19)
  Cheek 4 (3)
  Trigone 17 (14)
  Oropharynx 8 (7)
  Palate 3 (2)
  Fornix 10 (9)
  Not specified 3 (2)
Histologic grade
  Low 35 (29)
  Intermediate 65 (54)
  High 21 (17)
AJCC stage
  I 11 (9)
  II 30 (25)
  III 28 (23)
  IV 52 (43)
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with PBS, the slides were treated with biotinylated species-
specific secondary antibodies and streptavidin-biotin enzyme 
reagent (Dako, Glostrup, Denmark), and the colour developed 
by 3,3'-diaminobenzidine tetrahydrochloride. Sections were 
counterstained with Mayer's hematoxylin and mounted using 
xylene-based mounting medium. In negative controls, the 
primary antibody was omitted. The results of the IHC were 
separately evaluated by two independent observers by care-
fully examining the entire section with an optical microscope 
(Olympus BX41). For each case, the presence and the extent 
of positive cells in all sections examined was determined. 
Isolated tumour cells (ITCs) are defined as tumour cell 
clusters that are not >0.2 mm in largest diameter and are 
denoted as lymph node negative (pN0[i+]). Micrometastases 
are defined as metastases that are >0.2 mm in diameter but 
≤2 mm, denoted as lymph node positive (pN1mi). Carcinoma 
macrometastases measured >2 mm in maximum extent. Two 
investigators experienced in oral pathology blindly and inde-
pendently examined the study sections initially, and then they 
evaluated together the histopathological and immunostained 
sections until they reached an agreement.
Statistical analysis. Data were analysed by the GraphPad 
Prism software version 5.0 for Windows (GraphPad Soft-
ware, San Diego, CA, USA; www.graphpad.com) and Excel 
Microsoft Office. Differences among the groups were 
estimated using the one-way analysis of variance (ANOVA) 
and the Student-Newman-Keuls test. Only P-values <0.05 
were considered significant. Overall survivals in the different 
groups were calculated by the Kaplan-Meier curves and log-
rank (Mantel-Cox) test was applied for comparing survival 
probabilities. The pathological positivity of the ND (pN+) and 
the type of LNMs were correlated with the site of primary 
tumour. The percentages of positive node metastases (pN+) 
in elective, therapeutic and secondary to SLN+ NDs and the 
number of lymph nodes harvested were also evaluated.
Results
Differentiation degree, cTNM staging and pN status of 121 
cases. Patient demographics and characteristics such as gender, 
OSCC site, primary tumour differentiation grading and cTNM 
staging according to the international guidelines (2) of the 121 
OSCCs considered are shown in Table I.
At pre-surgical clinical-instrumental evaluation, 61/121 
cases (50%) were considered positive (cN+) and 60/121 (49%) 
negative (cN0) to node metastases. The histopathological 
lymph node assessment subsequent to ND revealed at least 
one node metastasis in 56/121 NDs, thus considered pathologi-
cally positive lymph nodes (pN+) and no node metastasis in 
the remaining 65 cases, which were considered pathologically 
negative lymph nodes (pN0). The percentages of true positive 
(cN+ and pN+), true negative (cN0 and pN0), false positive 
(cN+ and pN0) and false negative (cN0 and pN+) were 87, 95, 
13 and 5% respectively, as reported with details of accuracy, 
sensitivity, specificity, and positive and negative predictive 
values in Fig. 2.
The pN+ distribution according to the grading, staging 
MRND intent and, conversely, the pN+ frequency in each 
group are reported in Table II.
Distribution of 121 MRNDs according to intent to surgery 
and related pN+ frequencies. Among the 121 NDs considered, 
61/121 (50%), presenting at least a clinical node involvement 
(cN+), were therapeutic NDs; 19/121 (16%), presenting a 
cT3/cT4 and cN0 were elective NDs; the remaining 41/121 
(34%), presenting primary tumours small in size (cT1/cT2) 
and no evident clinical node metastases (cN0) but positive to 
sentinel lymph node metastases (SLN+) during the intraopera-
tive assessment of sentinel lymph node, were NDs performed 
to establish the presence of other node metastases in addition 
to SLN+ (Table II). The distribution of 56 pN+ according to 
clinical-instrumental indications and, conversely, the pN+ 
frequency in each indication are reported in Table II.
pN+ pattern. After excluding 19 pN+ cases due to lack of 
data useful to classify the pN+ histopathological pattern, the 
remaining 37 pN+ NDs were distinguished into 17/37 with 
typical (46%) and 20/37 with atypical (54%) node metastases 
according to Woolgar's classification (21). The atypical pattern 
was largely represented by skip metastases [10/20 (50%)], 
followed by the frequency of bilateral metastases [5/20 (25%)], 
micrometastases [2/20 (10%)], involvement of other lymph 
nodes alone [2/20 (10%)], and 1/20 (5%) showing both micro-
metastases and other lymph nodes co-interested (Fig. 3A). 
According to primary tumour site, skip metastases indiscrimi-
nately involved any site of the oral cavity, except check and 
fornix, which, on the contrary, preferentially showed micro-
metastases; bilateral metastases were frequently detected in 
OSCCs affecting tongue as a single site or in association with 
floor of the mouth or trigone; ‘other different lymph nodes’ 
were involved in floor of the mouth tumours (Fig. 3B and C).
Among 56 pN+ cases, 15/56 pN+ (26.8%) involved levels 
I-III, 11/56 pN+ (19.6%) involved levels IV-V, and 30/56 
(53.6%) pN+ were censored due to level not reported.
ND anatomical levels I-III were typically involved by node 
metastases while levels IV-V showed pN+ only for primary 
tumours of trigone, floor of the mouth plus tongue, tongue 
alone and multiple sites (data not shown).
Number of lymph nodes removed. A total of 3,390 lymph 
nodes were harvested in 121 NDs, mean 18.5±22.7 per ND, 
Figure 2. Flow chart showing the cases analysed in the study and the accu-
racy, sensitivity, specificity and predictive values of the clinical instrumental 
approach. Accuracy, 90.9%; sensitivity, 0.946; specificity, 0.877; PPV1, 
8.869; NPV2, 0.950; 1PPV, positive predictive value; 2NPV, negative predic-
tive value. 
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range 1-110. One hundred and sixty-two lymph nodes were 
pN+ in 56 NDs, mean 2.9±0.03, range 1-10.
Recurrence. Recurrence was observed in 8 cases, whose clinical, 
histological and lymph node features are shown in Table III.
Survival curves. Overall survival statistical significance and 
percentages of subjects alive at 1, 2 and 5 years from the diag-
nosis are reported in Table IV.
Overall survival was statistically different according to 
early AJCC vs. late AJCC stages (P=0.0004) with a 5-year 
Table II. pN+ distribution and frequency according to histological grading, AJCC staging and MRND intent.
  pN+ distribution Total pN+ cases
Histological grade Total ND cases (%) according to grade in each group
Low 35 (29) 11/56 (20) 11/35 (31)
Intermediate 65 (54) 32/56 (57) 32/65 (49)
High 21 (17) 13/56 (23) 13/21 (62)
  pN+ distribution Total pN+ cases
cTNM Total ND cases (%) according to cTNM in each group
Stage I 11 (9) 0/56 (0) 0/11 (0)
Stage II 30 (25) 2/56 (4) 2/30 (6.6)
Stage III 28 (23) 13/56 (23) 13/28 (46.4)
Stage IV 52 (43) 41/56 (73) 41/52 (79)
  MRND clinically Total ND  pN+ according Total pN+ cases
cT status cN status accorded cases (%) to MRND intent in each group
Any T cN+ Therapeutic 61/121 (50) 53/56 (94) 53/61 (88.3)
T3 or T4 cN0 Elective 19/121 (16) 1/56 (2) 1/19 (5.3)
T1 or T2 cN0 Secondary to SLN+ 41/121 (34) 2/56 (4) 2/42 (4.8)
Figure 3. Atypical metastatic pattern frequencies (A) and their distributions (B and C) according to primary tumour site. (C) Distribution of the 19 pN+ atypical 
metastases according to pattern and primary tumour site. The case showing both micrometastases and other lymph nodes co-interested has not been included. 
Ln, lymph node; T, tongue; PIL, pillars; F, fornix; FOM, floor of the mouth; TR, trigone; C, cheek.
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survival of 78.34 and 46.16%, respectively, and according to 
absence/presence of nodal metastases (pN0 vs. pN+, P=0.0003) 
with a 1-5 year overall survival ranging between 97-74% in 
pN0 cases and between 69-54% in pN+ cases.
Overall survival according to histological grade and typical 
vs. atypical lymph nodal metastatic pattern did not reach 
statistical significance when independently considered or when 
together. When comparing pN0 subjects, pN+ with macrometas-
tases or ECS and pN+ with micrometastases, patients reporting 
pN+ with micrometastases showed an intermediate probability 
of survival after 5 years and these data were statistically signifi-
cant (P=0.004). With regard to the number of lymph nodes 
harvested, statistically significant different survivals (P=0.005) 
were found in cases with >30 lymph nodes harvested, whose 
5-year survival was >80% compared to 46.93% in cases with 
<20 lymph nodes and 66.67% in the 20-30 lymph node group, 
independently of the pN status.
With regard to intent to surgery, overall survival among 
subjects who had undergone elective, therapeutic and after 
SLN+ NDs were always statistically significant with the worst 
prognosis in patients who had undergone therapeutic ND and 
the most positive one in patients who had undergone ND after 
SLN+. pN status did not appear to be responsible for differ-
ences in survival since patients with pN0/therapeutic MRND 
showed a 15% 5-year survival compared to pN+/therapeutic 
MRND patients with a 45.72% 5-year survival.
Discussion
In the present study, a descriptive and statistical retrospective 
study on 121 OSCCs who had undergone neck dissection 
(ND) was conducted, focusing on metastatic pattern (typical 
vs. atypical), number of lymph nodes harvested and node 
metastasis features in terms of size, anatomical extent and 
surgical decision orienting the ND (elective, therapeutic and 
after SLN+).
Correlation among histological malignancy grading in 
OSCC and different clinical parameters such as clinical 
staging, recurrence and prognosis have been published in 
different studies and a close relationship between the degree 
of histological differentiation and the incidence of lymph node 
metastasis (LNM) has been reported by several investigators 
in an attempt to identify a better prognosis. Our results are 
partly in accordance with previous literature (23).
Descriptive data showed, as expected, that the more the 
primitive tumour was towards undifferentiation and AJCC 
advanced staging, the more frequent the nodal metastases. 
Despite these findings, statistically significant differences in 
the overall survival were observed only in relation to staging 
and not according to grading.
Since 88.3% of NDs performed for therapeutic intent 
presented at least one pN+, the therapeutic value was 
confirmed. On the contrary, the low pN+ frequencies in 
elective NDs (5.3%) and in NDs secondary to SLN+ (4.8%) 
revealed an overtreatment in the remaining 94.7 and 95.2% 
of cases, respectively. pN+ was found in 2 out of 42 NDs 
performed after SLN+ (0/11, 0%, pN+ in cT1-cN0M0 NDs 
and 2/31, 6.45%, in cT2-cN0M0 NDs), thus confuting 
previous literature supporting its role as a diagnostic marker 
for other nodal metastases (24,25) and bringing the predictive 
role of SLN positivity into discussion, leading us to conclude 
that an ND secondary to SLN+ is an overtreatment in 100% 
of cT1-cN0M0 NDs and in 93.55% of cT2-cN0M0 NDs. We 
suggest conducting further biomolecular studies focusing on 
molecular markers able to predict occult metastatic disease 
in SLN biopsies, thereby improving the quality of the treat-
ments (26).
The significant association between clinical staging and 
histopathological report, confirmed by high accuracy (90.9%) 
revealed the quality of the pre-surgical clinical and instru-
mental staging of the tumours.
With regard to the anatomical lymph nodal levels involved, 
results showing involvement of levels IV-V only for primary 
tumours of trigone, floor of the mouth plus tongue, tongue 
alone and multiple sites, express the major morbidity of the 
OSCCs of these primary sites, requesting an ND extended 
until level V and lead us to re-consider the extended ND 
in the cases of OSCC affecting different oral sites such as 
cheek, which never showed levels of IV-V involvement in the 
present study. Shah (27) provided evidence that the pattern 
of neck metastasis of carcinomas from upper aerodigestive 
tract is predictable based on the location of the primary 
lesion. Moreover, it has been shown that in patients with oral 
carcinoma and clinical evidence of neck disease, the rate of 
pathologic involvement of level V nodes was only 4%. In the 
present study, the percentage of pathologic involvement of 
level IV-V nodes was 19.6%, higher when compared with the 
4% value reported by Shah (27).
Table III. Clinical, histological and lymph node features in the 8 cases with recurrence.
Gender Age (years) T site Histological grade AJCC stage pN status Outcome
Female 80 FOM Low II pN0 Alive
Female 83 FOM Intermediate III pN+ Alive
Female 48 Tongue Intermediate IV pN+ Alive
Female 70 Tongue Low I pN0 Deceased
Male 64 Tongue Intermediate II pN0 Deceased
Male 57 FOM, Tongue Intermediate IV pN+ Alive
Male 70 Fornix Intermediate III pN+ Deceased
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Recurrences, observed in 8 cases, mainly occurred in floor 
of the mouth and tongue OSCCs, at intermediate grade of 
differentiation and independently from the pN status.
The survival probability was in accordance with the 
number of lymph nodes harvested, as previously demonstrated 
by Amar et al (6), who found the larger number of lymph nodes 
dissected in the ND related to the group of better prognoses 
among pN0 cases, while we found this result independently 
from the pN status.
We also confirmed the statistically significant different 
survival probability of patients with micrometastases (5-year, 
40%), intermediate among pN0 (5-year, 69.10%) and pN+ 
with macrometastases patients (5-year, 28.68%), as previously 
reported by Broglie et al (20) and Han et al (28).
Table IV. One-, 2- and 5-year overall survival and the statistical significance.
 1-year (%) 2-year (%) 5-year (%) P<0.05
Stage I-II 90.00 87.50 78.34 Yes
Stage III-IV 76.16 50.78 46.16
Low grade 83.24 68.65 68.65 No
Intermediate-high grade 81.11 64.95 51.45
pN0 93.54 94.54 69.11 Yes
pN+ 66.03 45.41 45.41
pN+/Stage I-IIa 0 0 0 Yes
pN+/Stage III-IV 67.46 46.20 46.20
pN+/Low grade 50.00 41.66 41.66 No
pN+/Intermediate-high grade 69.35 44.56 44.56
Typical pN+ 50.89 44.53 44.53 No
Atypical pN+ 72.22 41.27 41.27
Typical pN+/Low grade 50.00 50.00 50.00 No
Typical pN+/Intermediate-high grade 51.56 51.56 51.56
Atypical pN+/Low grade 78.57 34.37 34.37
Atypical pN+/Intermediate-high grade 50.00 25.00 25.00
pN+ with ECS/macrometastases  80.67 28.68 28.68 Yes
pN+ with micrometastases 80.00 40.00 40.00
pN0 93.54 81.50 69.10
LN<20 72.38 52.36 46.93 Yes
LN 20-30 88.80 66.67 66.67
LN>30 96.29 87.59 80.60
pN0/Elective 87.50 79.54 62.64 Yes
pN0/Therapeutic  87.50 30.00 15.00
pN0/SLN+ 100.00 94.51 84.63
pN+/Elective 100.00 100.00 100.00
pN+/Therapeutic 68.10 45.71 45.71
pN+/SLN+b 0 0 0
SLN+ 95.00 89.79 80.40 Yes
E 88.23 80.88 65.36
T 70.745 42.86 39.56
pN+/SLN+ 100.00 95.52 84.63 Yes
pN+/E 100.00 100.00 100.00
pN+/T 68.11 45.72 45.72
pN0/SLN+ 100.00 94.52 84.63 Yes
pN0/E 87.50 71.59 62.64
pN0/T 87.50 30.00 15.00
aThere were 2 pN+/Stage I-II subjects. bThe 2 patients pN+/SLN+ died after 9 months.
CONTALDO et al:  PROGNOSTIC SIGNIFICANCE OF LYMPH NODE METASTATIC FEATURES IN ORAL CARCINOMA8
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
Statistically significant difference in the overall survival 
was also found according to clinical intent to surgery indepen-
dently from the pN0, with a better prognosis in patients who 
had undergone elective ND or after SLN+ when compared with 
the ones who had undergone therapeutic ND, independently 
from pN status.
In conclusion, the surgical management of regional meta-
static neck disease in patients with oral and oropharyngeal 
cancer remains a topic of debate and controversy. For several 
years classical comprehensive ND has been the mainstay 
of treatment. Selective and super-selective neck treatments 
were recently introduced and widely applied in order to 
reduce morbidity and mortality related to extensive ND, thus 
improving the postoperative quality of life after preservation 
of level V and the surrounding anatomical structures.
With regard to atypical metastases according to Woolgar's 
definitions, no statistically significant differences were found 
related to the overall survival of this group vs. typical meta-
static pattern. However, we noted different atypical features 
related to different primary tumour sites. Our data suggest that 
enhancing our knowledge of these types of atypical patterns 
site-related, and further evaluations such as novel imaging 
techniques (29) and molecular analyses (30) may help us to 
understand if any behaviour and biomolecular differences 
exist among OSCCs according to site.
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